MPS Limited Board Approves Audited FY26 Results; Appoints KPMG as Internal Auditors
MPS Limited approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026. KPMG appointed as Internal Auditors for three years (FY27-FY29). Walker Chandiok & Co LLP re-appointed as Statutory Auditors for five years. No final dividend recommended for FY26.
The approval of financial results and auditor appointments are significant routine corporate actions. The decision on dividend, while not a high impact event in isolation, is a material consideration for investors. The appointment of internal auditors for a multi-year term and re-appointment of statutory auditors provide stability.
The announcement contains routine corporate actions like approval of financial results, appointment/re-appointment of auditors, and a decision on dividend. While the appointment of new internal auditors and re-appointment of statutory auditors are standard, the decision not to recommend a dividend is a neutral event for this period.
MPS Limited announced the outcome of its Board Meeting held on Friday, 15 May 2026. The Board approved the Audited Financial Results (Standalone and Consolidated) for the Fourth Quarter (Q4) and the Financial Year ended 31 March 2026. The Statutory Auditors, M/s. Walker Chandiok & Co LLP, have issued an unmodified opinion on these results.
Following a recommendation from the Audit Committee, the Board approved the appointment of M/s. KPMG Assurance and Consulting Services LLP (“KPMG”) as the Internal Auditors for the Company and its Material Subsidiary, MPS Interactive Systems Limited. This appointment is for a term of three consecutive financial years, commencing from FY 2026-27 up to FY 2028-29. The aim is to align the internal audit framework across the Group.
Furthermore, M/s. Walker Chandiok & Co LLP were re-appointed as the Statutory Auditors for the Company and its Material Subsidiary for a second term of five consecutive years, starting from the conclusion of the upcoming 56th AGM until the 61st AGM (ending in 2031), subject to shareholder approval. This re-appointment aims to ensure consistency in audit methodology and reporting standards.
The Board decided not to recommend a final dividend for the financial year 2025-26, citing the deployment of cash flow towards the acquisition of Unbound Medicine, Inc. and the need to retain capital for future growth, consistent with the company's capital allocation framework.
The Board Meeting commenced at 10:30 hours and concluded at 13:55 hours.
What to do with a filing like this
MPS Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by MPS Limited. Read the original for the full detail.